Nature Communications (May 2020)
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
- Elaine Sanij,
- Katherine M. Hannan,
- Jiachen Xuan,
- Shunfei Yan,
- Jessica E. Ahern,
- Anna S. Trigos,
- Natalie Brajanovski,
- Jinbae Son,
- Keefe T. Chan,
- Olga Kondrashova,
- Elizabeth Lieschke,
- Matthew J. Wakefield,
- Daniel Frank,
- Sarah Ellis,
- Carleen Cullinane,
- Jian Kang,
- Gretchen Poortinga,
- Purba Nag,
- Andrew J. Deans,
- Kum Kum Khanna,
- Linda Mileshkin,
- Grant A. McArthur,
- John Soong,
- Els M. J. J. Berns,
- Ross D. Hannan,
- Clare L. Scott,
- Karen E. Sheppard,
- Richard B. Pearson
Affiliations
- Elaine Sanij
- Peter MacCallum Cancer Centre
- Katherine M. Hannan
- ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Australian National University
- Jiachen Xuan
- Peter MacCallum Cancer Centre
- Shunfei Yan
- Peter MacCallum Cancer Centre
- Jessica E. Ahern
- Peter MacCallum Cancer Centre
- Anna S. Trigos
- Peter MacCallum Cancer Centre
- Natalie Brajanovski
- Peter MacCallum Cancer Centre
- Jinbae Son
- Peter MacCallum Cancer Centre
- Keefe T. Chan
- Peter MacCallum Cancer Centre
- Olga Kondrashova
- The Walter and Eliza Hall Institute of Medical Research
- Elizabeth Lieschke
- The Walter and Eliza Hall Institute of Medical Research
- Matthew J. Wakefield
- The Walter and Eliza Hall Institute of Medical Research
- Daniel Frank
- The Walter and Eliza Hall Institute of Medical Research
- Sarah Ellis
- Peter MacCallum Cancer Centre
- Carleen Cullinane
- Peter MacCallum Cancer Centre
- Jian Kang
- Peter MacCallum Cancer Centre
- Gretchen Poortinga
- Peter MacCallum Cancer Centre
- Purba Nag
- QIMR Berghofer Medical Research Institute
- Andrew J. Deans
- Department of Medicine, St. Vincent’s Hospital, University of Melbourne
- Kum Kum Khanna
- QIMR Berghofer Medical Research Institute
- Linda Mileshkin
- Peter MacCallum Cancer Centre
- Grant A. McArthur
- Peter MacCallum Cancer Centre
- John Soong
- Senhwa Biosciences, Virginia Commonwealth University School of Medicine
- Els M. J. J. Berns
- Department of Medical Oncology, Erasmus MC Cancer Institute
- Ross D. Hannan
- Peter MacCallum Cancer Centre
- Clare L. Scott
- Peter MacCallum Cancer Centre
- Karen E. Sheppard
- Peter MacCallum Cancer Centre
- Richard B. Pearson
- Peter MacCallum Cancer Centre
- DOI
- https://doi.org/10.1038/s41467-020-16393-4
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 18
Abstract
Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and overcomes PARPi resistance in PDX models of HGSOC.
